Welcome to LookChem.com Sign In|Join Free
  • or
N-[2-(S)-(3,4-dichlorophenyl)-4-hydroxybutyl]-N-methyl-3-cyano-2-methoxy-1-naphthamide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

263387-98-0

Post Buying Request

263387-98-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

263387-98-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 263387-98-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,3,3,8 and 7 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 263387-98:
(8*2)+(7*6)+(6*3)+(5*3)+(4*8)+(3*7)+(2*9)+(1*8)=170
170 % 10 = 0
So 263387-98-0 is a valid CAS Registry Number.

263387-98-0Relevant academic research and scientific papers

Structural Analysis and Optimization of NK1 Receptor Antagonists through Modulation of Atropisomer Interconversion Properties

Albert, Jeffrey S.,Ohnmacht, Cyrus,Bernstein, Peter R.,Rumsey, William L.,Aharony, David,Alelyunas, Yun,Russell, Daniel J.,Potts, William,Sherwood, Scott A.,Shen, Lihong,Dedinas, Robert F.,Palmer, William E.,Russell, Keith

, p. 519 - 529 (2007/10/03)

We have previously described a series of antagonists that showed high potency and selectivity for the NK1 receptor. However, these compounds also had the undesirable property of existing as a mixture of interconverting rotational isomers. Here

Novel n-( 2-phenyl-3-aminopropyl)naphtamides

-

Page/Page column 7-8, (2010/02/05)

A compound of the formula wherein R1, R2, R3, R4, R5, R6, X1 and X2 are as defined in the specification useful for the treatment of diseases in which action of the neu

A new approach to the rapid parallel development of four neurokinin antagonists. Part 3. Assembly of neurokinin antagonists

Parker, Jeremy S.,Bowden, Sharon A.,Firkin, Catherine R.,Moseley, Jonathan D.,Murray, Paul M.,Welham, Matthew J.,Wisedale, Richard,Young, Maureen J.,Moss, William O.

, p. 67 - 73 (2013/09/05)

Four neurokinin antagonists were assembled using a rapid parallel development approach. Research Department processes were scaled up if process safety and robustness were not compromised. Using this approach, 1 kg of each compound was rapidly delivered fo

Design, synthesis, and SAR of tachykinin antagonists: Modulation of balance in NK1/NK2 receptor antagonist activity

Albert, Jeffrey S.,Andisik, Donald,Barthlow, Herbert,Bernstein, Peter R.,Bialecki, Russell A.,Dedinas, Robert,Dembofsky, Bruce T.,Hill, Daniel,Kirkland, Karin,Koether, Gerard M.,Kosmider, Benedict J.,Ohnmacht, Cyrus,Palmer, William,Potts, William,Rumsey, William,Shen, Lihong,Shenvi, Ashok,Sherwood, Scott,Aharony, David,Warwick, Paul J.,Russell, Keith

, p. 3972 - 3983 (2007/10/03)

Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 263387-98-0